AstraZeneca

AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

Address: da Vinci Building, Melbourn Science Park, Melbourn
Postcode: SG8 6EE
Country: United Kingdom
Website: http://www.astrazeneca.co.uk
Membership type:Enhanced Founder

Our skills focus on the discovery, development and commercialisation of medicines for the treatment of some of the world’s greatest healthcare challenges.  Our commitment to making a meaningful difference in healthcare is founded on the pursuit of scientific excellence that addresses unmet patient need. Science is at the heart of AstraZeneca’s future strategy and success – and our aspiration is to achieve scientific leadership. 

In March 2013, we announced our UK global R&D centre and corporate headquarters will be based at the Cambridge Biomedical Campus.  The new, purpose-built site will be home to around 2000 highly-skilled staff, as part of our plan to create strategic global R&D centres in Britain, the United States and Sweden.  This will bring together our small molecule and biologics activity, creating opportunities to capitalise on the promise of small and large molecule combinations, improving pipeline productivity and establishing AstraZeneca as a global leader in biopharmaceutical innovation.

The Biomedical Campus will also become our largest centre for oncology research, as well as hosting our work on cardiovascular and metabolic diseases, respiratory, inflammatory, autoimmune and nervous system conditions. Projects here will also include medicinal chemistry and high-throughput screening, and the facility will accommodate a number of pre-clinical research capabilities.

AstraZeneca has a long-standing presence in the UK and we're proud to be developing the next generation of medicines in Cambridge. 

AstraZeneca in Cambridge

AstraZeneca in Cambridge

In March 2013, we announced plans to establish a new Global R&D Centre and Corporate Headquarters in Cambridge on the Cambridge Biomedical Campus, the future home to approximately 2,000 employees. In February 2015, Cambridge City Council granted planning permission for our new site.

AstraZeneca in the UK

A global pharmaceutical company with a major UK presence. Through innovation and collaboration we can achieve better health for all.

AstraZeneca's first 'Start-Up Science' competition

Attention life science entrepreneurs! Enter AstraZeneca's 'Start-Up Science' competition

Are you an early-stage Cambridge start-up focused on life sciences/healthcare? Time is running out to enter AstraZeneca's first ever Start-Up Science competition for life science entrepreneurs in the Cambridge area.

25 May 2018Read in full

Report cover

Cambridge life sciences cluster set to deliver additional £1billion to the UK economy by 2032

The Cambridge life sciences cluster has the potential to contribute an additional £1bn to the UK economy by 2032, according to independent research commissioned by AstraZeneca.

4 May 2018Read in full

AstraZeneca and Lucy Cavendish collaborate

AstraZeneca and Lucy Cavendish College establish mentoring collaboration

AstraZeneca and Lucy Cavendish College, University of Cambridge, today announced that they have established a strategic collaboration to support their common goals of advancing women in science and business leadership, building on their existing relationship since the Company relocated its global HQ and R&D centre to Cambridge in 2016.

26 March 2018Read in full

AstraZeneca aims to advance clinical practice in CV risk management with new data at ACC 2018

At the American College of Cardiology (ACC) 67th Annual Scientific Session & Expo 2018 in Orlando, Florida, this weekend, AstraZeneca will deliver industry-leading science and insights that augment the body of evidence on clinical approaches to tackling cardiovascular diseases.

9 March 2018Read in full

MedImmune creates stand-alone company for early-stage inflammation and autoimmunity biologics

AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio. The new company will focus on developing medicines for severe autoimmune diseases by targeting the underlying causes of each disease.

28 February 2018Read in full

 Science Top Employer logo

It’s official: AstraZeneca and MedImmune ranked a top place for scientists to work by Science

AstraZeneca and MedImmune, its global biologics research and development arm, have been voted one of the top science employers worldwide, in the prestigious Science 2017 Top Employers Survey.

24 October 2017Read in full

Structure of a human ATM dimer

High tech collaboration reveals the dynamic structure of ATM

An advanced cryo-electron microscope allows AstraZeneca and Laboratory for Molecular Biology (LMB) scientists in Cambridge to uncover ground-breaking insights into a prime therapeutic target in cancer.

23 May 2017Read in full

AstraZeneca and Pieris Pharmaceuticals collaborate on treatments for respiratory diseases

AstraZeneca has announced a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals, Inc. to develop novel inhaled drugs that leverage Pieris’ Anticalin® platform. Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering the potential of direct delivery to the lung.

4 May 2017Read in full

AstraZeneca's bladder cancer drug gets FDA approval

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab).

1 May 2017Read in full

Tagrisso receives full approval in the EU

AstraZeneca today announced that the European Commission (EC) has granted full marketing authorisation for Tagrisso (osimertinib) 40mg and 80mg once-daily tablets for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

26 April 2017Read in full

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. ...
  12. 17
11/07/2018

Associate Director, Audit & Inspection

At AstraZeneca we work together across global boundaries to make an impact and find answers to challenges. We do this with the u...

Location: Cambridge
Salary: Competitive
More Info
24/05/2018

Talent Aquisition Partner - GMD

You will be responsible for developing and implementing Talent Acquisition strategies in partnership with the Human Resources Bu...

Location: Cambridge
Salary: Competitive
More Info